From: CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease
Characteristics | APOE genotype | ||||
---|---|---|---|---|---|
AD patients | 0 ε4 | 1 ε4 | 2 ε4 | ||
(N = 321) | (N = 125) | (N = 141) | (N = 55) | P value | |
Age, year, mean (SD) | 71.0 (8.5) | 71.4 (9.9) | 71.4 (7.6) | 69.0 (6.9) | 0.07 |
Women, n (%) | 200 (62.3) | 76 (60.8) | 87 (61.7) | 37 (67.3) | 0.70 |
MMSE, mean (SD) | 20.3 (5.8) | 20.4 (5.6) | 19.8 (5.9) | 21.4 (5.8) | 0.16 |
Level of education, n (%) | |||||
Low | 106 (35.7) | 48 (40.3) | 44 (33.9) | 14 (29.2) | |
Intermediate | 110 (37.0) | 38 (31.9) | 50 (38.5) | 22 (45.8) | |
High | 81 (27.3) | 33 (27.7) | 36 (27.7) | 12 (25) | 0.49 |
APOE ε4 carriers, n (%) | 196 (61.1) | – | – | – | – |
Years of follow-up, mean (SD) | 3.9 (2.4) | 3.8 (2.5) | 3.8 (2.4) | 4.1 (2.6) | 0.74 |
Death, n (%) | 57 (17.8) | 25 (20.0) | 24 (17.0) | 8 (14.6) | 0.65 |
Institution, n (%) | 71 (22.1) | 26 (20.8) | 35 (24.8) | 10 (18.2) | 0.54 |
CSF biomarkers, pg/mL, mean (SD) | |||||
Aβ42 | 483.8 (134.8) | 481.9 (136.1) | 512.1 (126.1) | 415.9 (130.8) | < 0.001 |
Aβ40b | 13,298 (5454) | 12,820 (5648) | 13,843 (5498) | 12,928 (4897) | 0.19 |
Ratio Aβ42/40b | 0.047 (0.022) | 0.049 (0.022) | 0.047 (0.024) | 0.040 (0.014) | 0.08 |
Tau | 684.9 (276.9) | 677.4 (271.4) | 705.2 (291.9) | 649.5 (248.1) | 0.61 |
p-Tau 181 | 102.6 (39.0) | 103.6 (46.4) | 103.8 (35.0) | 97.4 (29.6) | 0.60 |